JP2020515582A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515582A5
JP2020515582A5 JP2019553244A JP2019553244A JP2020515582A5 JP 2020515582 A5 JP2020515582 A5 JP 2020515582A5 JP 2019553244 A JP2019553244 A JP 2019553244A JP 2019553244 A JP2019553244 A JP 2019553244A JP 2020515582 A5 JP2020515582 A5 JP 2020515582A5
Authority
JP
Japan
Prior art keywords
tumor
cancer
use according
related macrophages
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019553244A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020515582A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/024770 external-priority patent/WO2017172930A1/en
Application filed filed Critical
Priority claimed from PCT/US2017/051662 external-priority patent/WO2018182776A1/en
Publication of JP2020515582A publication Critical patent/JP2020515582A/ja
Publication of JP2020515582A5 publication Critical patent/JP2020515582A5/ja
Pending legal-status Critical Current

Links

JP2019553244A 2016-03-29 2017-09-14 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート Pending JP2020515582A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662314688P 2016-03-29 2016-03-29
US201662323282P 2016-04-15 2016-04-15
US201662396409P 2016-09-19 2016-09-19
USPCT/US2017/024770 2017-03-29
PCT/US2017/024770 WO2017172930A1 (en) 2016-03-29 2017-03-29 Pbd conjugates for treating diseases
PCT/US2017/051662 WO2018182776A1 (en) 2016-03-29 2017-09-14 Folate conjugate for use in targeting tumor associated macrophages

Publications (2)

Publication Number Publication Date
JP2020515582A JP2020515582A (ja) 2020-05-28
JP2020515582A5 true JP2020515582A5 (enExample) 2020-10-22

Family

ID=59965167

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019553244A Pending JP2020515582A (ja) 2016-03-29 2017-09-14 腫瘍関連マクロファージの治療における使用のための葉酸コンジュゲート

Country Status (3)

Country Link
US (2) US20200323991A1 (enExample)
JP (1) JP2020515582A (enExample)
WO (1) WO2017172930A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3268046A4 (en) 2015-03-13 2018-11-21 Endocyte, Inc. Conjugates for treating diseases
CN110678204A (zh) * 2016-03-29 2020-01-10 恩多塞特公司 用于靶向肿瘤相关巨噬细胞的叶酸缀合物
WO2018031662A1 (en) * 2016-08-11 2018-02-15 Genentech, Inc. Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
WO2019104289A1 (en) * 2017-11-27 2019-05-31 Mersana Therapeutics, Inc. Pyrrolobenzodiazepine antibody conjugates
CN109824622B (zh) * 2019-02-27 2022-12-30 中国科学技术大学 一类细胞内形成纳米结构杀死癌细胞的前体药物及其制法
CN120535564B (zh) * 2025-07-24 2025-09-23 杭州诺泰诺和生物医药科技有限公司 一种含有Sar linker的多肽的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG185592A1 (en) * 2010-05-19 2012-12-28 Endocyte Inc Improved process for a folate-targeted agent
EP2675479B1 (en) * 2011-02-15 2016-01-13 Immunogen, Inc. Cytotoxic benzodiazepine derivatives
US9662402B2 (en) * 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
CN110627797A (zh) * 2012-12-21 2019-12-31 麦迪穆有限责任公司 用于治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
PE20170935A1 (es) * 2014-09-12 2017-07-13 Genentech Inc Anticuerpos anti-her2 e inmunoconjugados
CA2968837A1 (en) * 2014-11-25 2016-06-02 Endocyte, Inc. Methods of treating cancer by targeting tumor-associated macrophages
EP3268046A4 (en) * 2015-03-13 2018-11-21 Endocyte, Inc. Conjugates for treating diseases

Similar Documents

Publication Publication Date Title
JP2020515582A5 (enExample)
Leon et al. Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways
Kota et al. Pancreatic cancer: Stroma and its current and emerging targeted therapies
Mitra et al. Novel delivery approaches for cancer therapeutics
Lozada-Delgado et al. RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials
ES2548253T3 (es) Métodos para el tratamiento de tumores sólidos
Nazir et al. Nanomaterials in combating cancer: therapeutic applications and developments
JP2015520753A5 (enExample)
JP2016538257A5 (enExample)
Yin et al. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy
ES2471452T3 (es) Uso de 5-(2,6-di-morfolin-4-il-pirimidin-4-il)-4-trifluorometil-piridin-2-ilamina para el tratamiento de carcinoma de pulmón de células no pequeñas con resistencia adquirida a los moduladores del receptor del factor de crecimiento epid�rmico (EGFR).
PH12018550049A1 (en) Protein kinase inhibitor, preparation method and medical use thereof
JP2011510056A5 (enExample)
JP2016513661A5 (enExample)
JP2014512354A5 (enExample)
JP2014509659A5 (enExample)
NZ563774A (en) Inhibitors of VEGF receptor and HGF receptor signaling
EP3148336A1 (en) Use of eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer
JP2009536156A5 (enExample)
JP2017514806A5 (enExample)
JP2018062523A5 (enExample)
ES2401822T3 (es) Utilización de imidazoquinolinas para el tratamiento de enfermedades dependientes de EGFR o enfermedades que han adquirido resistencia a agentes que tienen como objetivo mienbros de la familia de EGFR
ES2826558T3 (es) Nuevas terapias para el cáncer
JP2016224056A5 (enExample)
JP2016504325A5 (enExample)